Study of tamoxifen associated endometrial changes in women with breast cancer: a prospective study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20233631Keywords:
Breast cancer, Endometrial thickness, Tamoxifen, Transvaginal ultrasonographyAbstract
Background: Studies have estimated that women with breast cancer on tamoxifen therapy have a greater risk of developing endometrial cancer. We undertook this study to correlate the ultrasonographic findings, hysteroscopy findings and endometrial pathology in breast cancer patients on tamoxifen.
Methods: This was a prospective study conducted over a period of two years. Patients of histologically proven breast cancer on tamoxifen treatment for more than a year were taken into the study. Transvaginal ultrasonography and hysteroscopic biopsy (if endometrial thickness on TVS was 8mm or more) was performed. SPSS software was used for statistical analysis of data.
Results: 23 patients had an endometrial thickness between 5-10 mm. 23 between 10.1-15 mm, 13 between 15.1-20 mm and only 1 patient had an ET of more than 20 mm with a mean of 12.27 mm. On Hysteroscopy 24 patients (51%) had a bald endometrium, 14 (29.8%) had hyperplastic endometrium and 9 (19.2%) had polypoid endometrium. On endometrial biopsy, 19 patients had atrophic endometrium, 14 had polypoid endometrium, 11 had non secretory and 7 had secretory endometrium, 1 patient had disordered proliferative endometrium, 1 as hyperplasia without atypia and 1 with complex hyperplasia. 2 were reported as adenocarcinoma.
Conclusions: Usage of tamoxifen is warranted in view of its benefits outweighing its risks, the need of a screening program for patients who receive tamoxifen for a prolonged period and the need for a hysteroscopic biopsy when the endometrial thickness is more than 8mm especially in the symptomatic patients.
References
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. Cancer J Clinic. 2011;61(4):212-36.
Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002; 20:2758-60.
Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE, Mittal K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol.1997;176:129-37.
Nachtigall LE. Tamoxifen and the uterus and endometrium. Lancet.1989;1:375-6.
De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet. 1991;36:127-30.
Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynaecol. 1993;81:660-4.
Markovitch O, Tepper R, Fishman A. Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy. Maturitas. 2008;59:387.
Markovitch O, Tepper R, Fishman A, et al. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients. Breast Cancer Res Treat. 2007;101: 185.
Jindal A, Mohi MK, Kaur M, Kaur B, Singla R, Singh S. Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy. J Mid-life Health. 2015;6:59-65.
Kochar S, Arora P, Chattopadhyay A. Tamoxifen Therapy for Breast Cancer and Endometrial Pathology. Med J Armed Forces India. 2005;61(4): 313-5.
Gerber B, Krause A, Muller H, Reimer T, Kulz T, Makovitzky J, et al. Effects of adjuvant tamoxifen on endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000;18:3464-70.
Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol. 1999;17:2050-4.
Cecchini S, Ciatto S, Bonardi R, Mazzotta A, Grazzini G, Pacini P, et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol.1996;60:409-11.
Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat. 1999;54(3):255-60.
Kedar Ro, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 1994;343:1318-21.
Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. AmJ Obstet Gynaecol. 1994;170:447-51.
Bernstein L, Deapen D, Cerhan JR. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999;91:1654.
MacMahon B. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol. 1997;24(1):122-39.
Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Internal Med. 2009;151(10):727-37.
Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66(2):233-7.
